INTRODUCTION {#SEC1}
============

Alternative polyadenylation (APA) is emerging as a new paradigm of post-transcriptional regulation ([@B1]) for \>70% of human genes. By changing the position of polyadenylation, APA can generate transcripts with diverse 3′ UTRs that contain distinct *cis*-regulatory elements, such as miRNA binding sites, leading to altered function, stability, localization and translation efficiency of target RNAs. The role of APA in human cancers is only beginning to be appreciated. Both proliferating and transformed cells have been shown to favor shortened 3′ UTRs, potentially leading to the activation of proto-oncogenes through evasion of miRNA-mediated repression. In addition, our recent study identified CFIm25 ([@B2]), a master APA regulator, as a glioblastoma (GBM) tumor suppressor gene, further underscoring the importance of APA in cancer development.

Several APA databases exist with varying scopes. The first-generation APA databases, i.e. PolyA_DB2 ([@B3]) and PACdb ([@B4]), provide a limited amount of APA sites mainly based on the small expressed sequence tag (EST) database. With the rapid progress of next-generation sequencing (NGS), the second-generation APA databases were recently developed leveraging the various partitioned NGS data. For example, APADB ([@B5]) and APASdb ([@B6]) use specialized NGS protocols for APA detection, e.g. PolyA-seq, while effective are still currently limited to only a few tissue types and diseases. Furthermore, what was not clearly established from these databases is how pervasive and recurrent APA is in large clinical cohorts across distinct cancer types. The largest source of data that could mitigate this limitation, The Cancer Genome Atlas (TCGA), has devoted significant efforts to characterize numerous genomic, epigenomic, and transcriptomic features in thousands of tumors; however, they lack a PolyA-seq platform for APA analysis.

To at least partially fill this knowledge gap, we recently developed a powerful bioinformatics algorithm DaPars ([@B7]), one of the first of its kind, for the *de novo* identification of APA events based on localized changes in 3′ UTR RNA-seq read density between tumors and matched normal tissue (normals). DaPars has been shown to accurately detect the majority of APA events in our computational and experimental validations ([@B7]). We have applied DaPars to 358 TCGA tumor/normal pairs and revealed 1,346 recurrent APA target genes. Strikingly, the majority of APA events have shorter 3′ UTRs in cancers and tend to be more up-regulated in tumors, supporting the previous cell line model ([@B1]) that genes are up-regulated by shortening 3′ UTRs to escape miRNA-mediated repression. However, in other TCGA tumors beyond those 358 we previously reported, the critical target genes subject to APA, remain poorly understood.

Here we present The Cancer 3′ UTR Atlas (TC3A) as a new web resource of APA usage in human cancers. TC3A distinguishes itself in several ways: (i) TC3A, to the best of our knowledge, is the first repository to host a comprehensive compilation of APA events for more than ∼10,537 tumors across 32 cancer types ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). (ii) TC3A builds upon a proven user-friendly interface cBioPortal and provides visualizations and analytic functions in addition to data querying and download. TC3A users can easily explore the effects of APA usage using survival analysis and correlation analysis. (iii) TC3A uses standard RNA-Seq data to infer APA *de novo* events, which is a critical component because PolyA sequencing methods ([@B8],[@B9]) have not been widely adopted by the cancer community. In contrast, RNA-seq has been extensively used in almost every cancer genomics project including TCGA.

DATA COLLECTION AND DATABASE CONTENT {#SEC2}
====================================

We downloaded RNA-seq BAM files of 10,537 tumor samples across 32 TCGA cancer types from the UCSC Cancer Genomics Hub (CGHub). The original BAM files were then sorted and converted into bedgraph files using bedtools ([@B10]). Multiple bedgraph files within each cancer type were then jointly analyzed together to identify *de novo* APA sites with an updated version of DaPars that can handle multiple tumors samples without relying on normal tissues (<https://github.com/3UTR/DaPars2>).

For each transcript in tumors, we used a linear regression model to infer the exact location of APA site within 3′ UTR region from multiple tumor RNA-seq data by minimizing the deviation between the observed and the expected read density based on the two-polyA-site model, the most common model of APA regulation: $$\documentclass[12pt]{minimal}
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The degree of difference in APA usage in each tumor can be quantified as a change in Percentage of Distal polyA site Usage Index (ΔPDUI), which is capable of identifying 3′ UTR lengthening (positive index) or shortening (negative index).

DATABASE ORGANIZATION AND WEB INTERFACE {#SEC3}
=======================================

We organized APA usage data generated by DaPars into a series of MySQL tables. We adapted the original cBioPortal ([@B11]) web interface to our data and developed several analytical functions. cBioPortal is now the *de facto* standard among cancer biologists and clinical researchers who rely on TCGA datasets and has received nearly 2000 citations since 2013. With cBioPortal, researchers can easily access various molecular and clinical profiles from large-scale genomics datasets. These characteristics make cBioPortal a preferred foundation for TC3A.

Integrating APA data with cBioPortal {#SEC3-1}
------------------------------------

APA data is mathematically modelled as a two-dimensional matrix, or profile, where each cell represents a gene\'s PDUI value. The columns represent patient IDs and genes are indexed by rows. For each of the 32 cancer types, one such profile exists in the database. cBioPortal already provides all 32 cancer\'s genomic datasets. By aligning the patient ID and cancer type with existing cBioPortal datasets, APA data can be queried through various existing cBioPortal interfaces. To import the APA data, we used the dedicated importer module of cBioPortal. These APA data are then retrieved by Javascripts Ajax calls via Java Servlets end points. While doing on-demand analysis and plotting, Javascripts analyze data and call various plotting libraries to present the results.

The query interface {#SEC3-2}
-------------------

We adopted the original cBioPortal\'s main query interface (Figure [1A](#F1){ref-type="fig"}). Users can begin with typing the names of the genes in the box and the system will automatically detect any typos or alias and suggest corrections if necessary. An auxiliary table is provided to include all APA genes reported in the original DaPars paper ([@B7]). Genes can be searched and selected from this table. Cancer types are also specified in this interface and the available analysis functions will show up depending on the number of cancer types selected. When users choose multiple cancer types, the cross-cancer distribution analysis is available. If only one cancer type is selected, users can perform survival analysis and correlation analysis.

![Summary of TC3A. (**A**) TC3A main query interface. An auxiliary table provides all reported APA genes. (**B**) TC3A provides download links to all PDUI values indexed by genes or cancer types. (**C**) TC3A Correlation analysis: the gene EP300's PDUI value negatively correlates with its gene expression value. To reproduce: Choose cancer type Bladder Urothelial Carcinoma (BLCA) and gene EP300. Select the 'Plots' tab. In the 'Horizontal Axis' panel, select 'mRNA' as 'Profile Type' and 'PDUI' as 'Profile Name'. (**D**) Clinical data analysis: plot EIF2AK2's PDUI values against the disease stages. To reproduce: Choose cancer type Kidney Renal Clear Cell Carcinoma (KIRC) and gene EIF2AK2. Select the 'Plots' tab. In the 'Horizontal Axis' panel, select 'Clinical Attribute', then pick 'Neoplasm Disease Stage American Joint Committee on Cancer Code'. In the 'Vertical Axis' panel, select 'mRNA' as 'Profile Type' and 'PDUI' as 'Profile Name'. (**E**) Survival analysis using PDUI values. To reproduce, Choose cancer type Bladder Urothelial Carcinoma (BLCA) and gene EP300. Then select the 'Survival' tab and scroll down to look for the figure titled as 'APA Overall Survival Kaplan-Meier Estimate'. (**F**) The cross-cancer PDUI value distribution plot shows the overview of APA events cross multiple cancers.](gkx892fig1){#F1}

Data download {#SEC3-3}
-------------

Users can freely download PDUI values for genes of interest in the 'Download Data' panel. The full dataset can also be downloaded individually for each cancer type, as shown in Figure [1B](#F1){ref-type="fig"}.

Correlation analysis {#SEC3-4}
--------------------

TC3A provides the function to examine the correlation of 3′ UTR usage with other molecular features. In Figure [1C](#F1){ref-type="fig"}, gene EP300's PDUI is reversely correlated with its mRNA gene expression. It is consistent with recent reports that binding by miR-132 to a site located after the annotated proximal polyA site can significantly reduce EP300's expression levels ([@B12]).

For any single gene, the portal also allows users to examine the association of a gene\'s PDUI values with its clinical data. In Figure [1D](#F1){ref-type="fig"}, we provide such an example where in kidney renal clear cell carcinoma (KIRC), the gene EIF2AK2's PDUI value is plotted against the neoplasm disease stage. The median PDUI values gradually reduced in later clinical stages.

Survival analysis {#SEC3-5}
-----------------

TC3A enables researchers to analyze which APA event impacts patient overall survival. Users can generate publication quality Kaplan-Meier plot with log-rank test *P*-value. In Figure [1E](#F1){ref-type="fig"}, we demonstrate an example using gene EP300, a known APA gene from PolyA_DB2 ([@B3]). Using only its PDUI values to separate patient groups, we observed a significant longer survival in bladder cancer patients with 3′ UTR shortening. In comparison, when using only its genomic data, the patients cannot be effectively separated. This is in accordance with our previous report that APA data may better predict patient survival ([@B7]).

Cross-cancer distribution analysis {#SEC3-6}
----------------------------------

When multiple cancer types are selected, in the 'Expression' tab, a box plot shows the overview of PDUI distribution in each cancer type for the gene of interest. Users can easily discover the cancer types that have dramatic APA changes. In Figure [1F](#F1){ref-type="fig"}, the cross-cancer distribution plot shows the PDUI values of gene EP300 across different cancer types.

DISCUSSION {#SEC4}
==========

We present TC3A as a resource of APA usage for 10,537 tumors across 32 cancer types. This unique resource focuses on human cancers and utilizes routinely available large-scale RNA-Seq datasets from TCGA. Recent reports suggest that APA events are likely to be novel prognostic biomarkers for survival ([@B7],[@B13]). It is therefore urgent to add APA usage as an additional dimension to existing cancer genomic analysis. In TC3A, we compiled APA events detected by our updated method DaPars ([@B7]). We then systematically integrated APA with existing cancer data from TCGA within the framework of cBioPortal, a preferred database interface by cancer researchers. In this version of TC3A data release, we provide APA data for 10,537 tumors across 32 cancer types. Due to the limitations of DaPars, we used the annotated 3′UTR region as distal polyA site without including the lengthening events, and other APA events occurred outside of 3′UTR regions were not considered such as coding region APA ([@B14]). The 3′UTR usage calculated for each transcript was based on two-polyA site model, thus a few genes containing more than two polyA sites may be under-represented. It is expected with the increasing number of RNA-Seq datasets from Genomic Data Common (GDC, <https://portal.gdc.cancer.gov/>) and other similar consortium projects such as International Cancer Genome Consortium Data (ICGC) ([@B15]), TC3A will grow by incorporating newly generated RNA-seq data in the future. In summary, TC3A will enable biologists to explore functional consequences of APA events in human cancers, together with other genomics profiles in cBioPortal.
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